3.1 Comparison of general baseline data between MACE group and
non-MACE group
Over a median 40.56±18.33month follow-up period, 30/357 patients
(8.40%) were lost to follow-up. Those with incomplete data (n = 3) and
patients < 18 years (n = 24) were excluded from this report.
Finally, 300 HCM patients were included in our final analyses.Of these patients, 39.00% (117/300) suffered from a MACE, including 40
cases of all-cause death, 29 cases of cardiovascular mortality. Patients
were thus separated into a MACE group and a non-MACE group (183 and 117
patients, respectively). Compared to those in the non-MACE group,
patients in the MACE group were older, and had higher rates of coronary
artery disease (CAD) and atrial fibrillation (AF). Individuals in the
MACE group also exhibited lower Hb, HCT, and MCHC but higher serum Cr,
NT-proBNP, LVMI and RDW levels compared to those in the non-MACE group
(P <0.05). (Table 1)